🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

📑Our #portfolio company synendos featured in 👏👏 "Top 15 Swiss #Biotech #Startups Making a Difference in #Europe" by Labiotech.eu labiotech.eu/best-biotech/b… #vc #innovation #CNSdisease #neuropsychiatry

Synendos with Andrea Chicca is delighted to be featured in the Top 15 #Swiss #Biotech Startups Making a Difference in Europe by Labiotech.eu. ➡️ labiotech.eu/best-biotech/b… #innovation #endocannabinoid #neuropsychiatry #CNS

We are proud to belong to the nominated TOP 100 Swiss Startups in the Public Voting 2021. You can vote at startup.ch/Synendos and support Andrea Chicca and the @Synendos Team. #TOP100SSU #Innovation #endocannabinoid #neuropsychiatric #teamwork #biotech

We are delighted to race towards the top. Last Chance to support synendos in the TOP 100 Swiss Startups Public Voting 2021. Vote now ➡️startup.ch/Synendos #TOP100SSU #Innovation #CNS #endocannabinoid #biopharma #neurology #stressdisorders #neuropsychiatric #biotech #teamwork

"The twelve years funding allowed us to pursue our exciting, high-risk idea" said Prof. Jürg Gertsch GertschGroup and PD Dr. Andrea Chicca Andrea Chicca co-founders of synendos, a spin-off from Universität Bern & @NCCR_TransCure Swiss National Science Foundation - in German Laborjournal laborjournal.de/editorials/226…

Great achievement synendos !

Synendos is thrilled to announce the formation of the Scientific Advisory Board composed of prominent scientists and clinicians with significant CNS expertise. #CNS #endocannabinoid #neurology #stressdisorders #neuropsychiatric 👉Full press release: synendos.com/post/october-2…

Great news #Synendos!

We are hiring! We are looking for a Head of Preclinical and Translational Neuropharmacology. 👉To apply, check our website: synendos.com/openpositions

Accounting for 33% of exports, life science is a major business in Switzerland. Innovation is strongly powered by biotech startups. Meet the 15 companies that scored in the TOP 100 Swiss Startup Award 2021: top100startups.swiss/The-TOP-Swiss-… #TOP100SSU #SwissStartups #Biotech

With the support of #InnoBoosterGRS, Andrea Chicca and his team at synendos are developing breakthrough safe and effective therapies for neuropsychiatric disorders such as anxiety, mood and stress-related disorders. Universität Bern youtu.be/EUbYnqOhu0Y

We are hiring! We are looking for a Head of Translational Neuropharmacology. 👉To apply, check our website: synendos.com/openpositions

Read about the path that led @NCCR_TransCure and @Gertschlab to launch synendos, an NCCR TransCure spin-off, representing a tangible result of the translational research, in their LAST newsletter #scientificnews #translationalmedicine #biotech #neuroscience #CNS #endocannabinoid

Looking forward to joining the #SWISSPavilion and #SwissBiotech in Leipzig at #BIOEUROPE2022!

Great achievement for synendos. Thanks Innosuisse for the prestigious certificate!

Looking foreard to #BIOEuropeSpring2022!

Looking forward to sharing my experience with synendos ! #startups #biotech #SERI #Neurology #Psychiatry

@Synendos today announces that co-founder and SAB member Prof. Jürg Gertsch presented groundbreaking findings on an #endocannabinoid transporter at the 10th Gordon Research Conferences, informing and augmenting Synendos' pioneering ECS pipeline development. Read more: synendos.com/post/july-2023…

Looking very much forward to sharing my journey from Academia to entrepreneurship with synendos ! #innovation #entrepreneurship #startup #Switzerland

@Synendos is excited to announce the publication of the latest article written by Andrea Chicca and Jürg Gertsch, “CNS Drug Discovery in Academia: Where Basic Research Meets Innovation“ on ChemBioChem. #Biotech #Academia #drugdiscovery #ChemBioChem